Disitertide

CAS No. 272105-42-7

Disitertide( P144 | P144 Peptide )

Catalog No. M13832 CAS No. 272105-42-7

Disitertide (P144) is a TGF-β1 antagonist peptide.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 351 In Stock
10MG 597 In Stock
25MG 1269 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Disitertide
  • Note
    Research use only, not for human use.
  • Brief Description
    Disitertide (P144) is a TGF-β1 antagonist peptide.
  • Description
    Disitertide (P144) is a TGF-β1 antagonist peptide; induces apoptosis in GBM cell lines and reduces SMAD2 phosphorylation with downregulation of SKI and an upregulation of SMAD7 at both transcriptional and translational levels; active in vivo.Brain Cancer Phase 2 Clinical
  • In Vitro
    Disitertide (P144, 100 μg/mL) suppresses the protein expression levels of PI3K and p-Akt, and induce the protein expression of Bax in MC3T3-E1 cells. Disitertide (TGF-β1 inhibitor) abrogates the MACC1- AS1 expression in GC cells, suggesting that targeting TGFβ signaling pathway may be a potential strategy to inhibit MSC-induced stemness and chemoresistance.Disitertide (10 μg/mL to 200 μg/mL) affects proliferation, induces apoptosis as well as anoikis in A172 and U-87 MG GBM cell lines.Western Blot AnalysisCell Line:Mouse embryo osteoblast precursor MC3T3-E1 cells Concentration:100 μg/mL Incubation Time:4 h Result:Significantly suppressed the protein expression levels of PI3K and p-Akt, and induce the protein expression of Bax in MC3T3-E1 cells compared with the miR-590 group
  • In Vivo
    Disitertide (Topical application, 300 μg/mL) may promote scar maturation and improvement of hypertrophic scar morphology features in an “in vivo” model in nude mice after two weeks of treatment. Animal Model:Human hypertrophic scars were implanted in 60 nude mice. Dosage:300 μg/mL was added the Lipogel.Administration:Topical application daily administered.Result:Successful shedding was achieved in 83,3% of the xenografts.
  • Synonyms
    P144 | P144 Peptide
  • Pathway
    TGF-beta/Smad
  • Target
    TGFBR
  • Recptor
    TGFBR
  • Research Area
    Cancer
  • Indication
    Brain Cancer

Chemical Information

  • CAS Number
    272105-42-7
  • Formula Weight
    1580.824
  • Molecular Formula
    C68H109N17O22S2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO
  • SMILES
    CCC(C)C(C(=O)NC(C(C)CC)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(C)C(=O)NC(CCSC)C(=O)NC(CCSC)C(=O)NC(CCC(=O)N)C(=O)NC(CC(=O)N)C(=O)O)NC(=O)C(CO)NC(=O)C(C)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CO)NC(=O)C(C(C)O)N
  • Chemical Name
    L-Asparagine, L-threonyl-L-seryl-L-leucyl-L-α-aspartyl-L-alanyl-L-seryl-L-isoleucyl-L-isoleucyl-L-tryptophyl-L-alanyl-L-methionyl-L-methionyl-L-glutaminyl-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Gallo-Oller G, et al. Cancer Lett. 2016 Oct 10;381(1):67-75. 2. Baltanas A, et al. Antioxid Redox Signal. 2013 Nov 10;19(14):1607-18. 3. Diaz-Valdes N, et al. Cancer Res. 2011 Feb 1;71(3):812-21.
molnova catalog
related products
  • R-268712

    R-268712 is a potent, selective, orally active inhibitor of TGF-β type I receptor ALK5 with IC50 of 2.5 nM.

  • VU 0469381

    A potent, sellective BMP receptor ALK2 antaognist with Ki of 32 nM, with no affinity for ALK3/4/5/6.

  • TP-0427736

    TP-0427736 (TP0427736) is a novel potent and selective ALK5 inhibitor with IC50 of 2.72 nM, displays 300-fold selecitvity over ALK3.